Center/Research Area Affiliations
Dr. Miller’s clinical and research interests focus on retinal disorders, including age related macular degeneration (AMD), diabetic eye disease, and macular telangiectasia (MacTel). She and her colleagues at Mass. Eye and Ear pioneered the development of photodynamic therapy (PDT) using verteporfin (Visudyne®), the first pharmacologic therapy for AMD. Dr. Miller also identified the role of vascular endothelial growth factor (VEGF) in ocular neovascularization, forming the scientific basis of current antiangiogenic therapies for intraocular vascular diseases (including neovascular AMD and diabetic eye disease). Dr. Miller continues investigations to elucidate the pathophysiology of vision loss and improve therapies for retinal diseases.
Characterization and treatment of early and intermediate AMD: Dr. Miller aims to address the significant unmet need for improving phenotyping and treatments for early and intermediate AMD. Studies with Dr. Deeba Husain are designed to identify biomarkers capable of distinguishing subjects with AMD. Together with Dr. John B. Miller, Dr. Miller is investigating novel imaging techniques for detailed visualization of retinal structure, as this may be a relevant early marker for disease onset and allow for improved monitoring of disease progression. Dr. Miller also collaborates with Dr. Demetrios Vavvas to study statins as a possible treatment for early/intermediate AMD.
Neuroprotective therapies for retinal disease: Dr. Miller studies the mechanisms of photoreceptor and retinal pigment epithelium (RPE) cell death with the goal of developing new strategies for preserving vision. Together with Dr. Demetrios Vavvas, Dr. Miller aims to elucidate the mechanisms of photoreceptor cell death and to identify potential therapeutic targets through genetic, molecular, and cellular studies.
Structure-function correlation and imaging: Dr. Miller is working with Dr. Deeba Husain and Dr. John B. Miller to examine new testing methods combining retinal structure and visual function to better detect early visual defects.
The MacTel Project: Dr. Miller is an investigator in a collaborative research effort to identify the causes and appropriate treatments for this idiopathic condition. Mass. Eye and Ear served as a site for the Phase II ciliary neurotrophic factor (CNTF) trial for MacTel with Dr. Miller as an Investigator.
For a complete list of publications, please see her CV.
- Laíns I, Kelly RS, Miller JB, Silva R, Vavvas DG, Kim IK, Murta JN, Lasky-Su J, Miller JW, Husain D. Human Plasma Metabolomics Study across All Stages of Age-Related Macular Degeneration Identifies Potential Lipid Biomarkers. Ophthalmology. 2018 Feb; 125(2):245-254. doi: 10.1016/j.optha.2017.08.008. Epub 2017 Sep 12. PubMed ID PMID: 28916333.
- Miller JW, Bagheri S, Vavvas DG. Advances in Age-related Macular Degeneration Understanding and Therapy. US Ophthalmic Rev. 2017 Fall;10(2):119-130. doi 10.179225/USOR.2017.10.02.119. PubMed ID PMID: 29142592.
- Laíns I, Miller JB, Park DH, Tsikata E, Davoudi S, Pierce J, Silva R, Chen TC, Kim IK, Vavvas D, Miller JW, Husain D. Structural Changes Associated with Delayed Dark Adaptation in Age-Related Macular Degeneration. Ophthalmology. 2017 Sep; 124(9):1340-1352. doi: 10.1016/j.ophtha.2017.03.061. Epub 2017 May 10. PubMed ID PMID: 28501377.
- Vavvas DG, Daniels AB, Kapsala ZG, Goldfarb JW, Ganotakis E, Loewenstein JI, Young LH, Gragoudas EG, Eliott D, Kim IK, Tsilimbaris MK, Miller JW. Regression of some high-risk features of age-related macular degeneration (AMD) in patients receiving intensive statin treatment. EBioMedicine. 2016 Feb 4;5:198-203. doi:10.1016/j.ebiom.2016.01.033. eCollection 2016 Mar. PubMed PMID: 27077128; PubMed Central PMCID: PMC4816836.
- Miller JW. VEGF: From Discovery to Therapy: The Champalimaud Award Lecture. Transl Vis Sci Technol. 2016 Mar 11;5(2):9. eCollection 2016 Mar. PubMed PMID: 26981331; PubMed Central PMCID: PMC4790434.
View a complete list of publications on pubmed.gov »
View publications on Google Scholar »